Authors: Hart, TK Cook, RM Zia-Amirhosseini, P Minthorn, E Sellers, TS Maleeff, BE Eustis, S Schwartz, LW Tsui, P Appelbaum, ER Martin, EC Bugelski, PJ Herzyk, DJ

Citation: Tk. Hart et al., Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys, J ALLERG CL, 108(2), 2001, pp. 250-257

Authors: Herzyk, DJ Gore, ER Polsky, R Nadwodny, KL Maier, CC Liu, S Hart, TK Harmsen, AG Bugelski, PJ

Citation: Dj. Herzyk et al., Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice, INFEC IMMUN, 69(2), 2001, pp. 1032-1043

Authors: Bugelski, PJ Herzyk, DJ Rehm, S Harmsen, AG Gore, EV Williams, DM Maleeff, BE Badger, AM Truneh, A O'Brien, SR Macia, RA Wier, PJ Morgan, DG Hart, TK

Citation: Pj. Bugelski et al., Preclinical development of keliximab, a Primatized (TM) anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model andsafety studies, HUM EXP TOX, 19(4), 2000, pp. 230-243

Authors: Sharma, A Davis, CB Tobia, LAP Kwok, DC Tucci, MG Gore, ER Herzyk, DJ Hart, TK

Citation: A. Sharma et al., Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4, J PHARM EXP, 293(1), 2000, pp. 33-41

Authors: Gossett, KA Narayanan, PK Williams, DM Gore, ER Herzyk, DJ Hart, TK Sellers, TS

Citation: Ka. Gossett et al., Flow cytometry in the preclinical development of biopharmaceuticals, TOX PATHOL, 27(1), 1999, pp. 32-37